Corem signs lease agreement with Rarity Bioscience for 1,300 sq.m. in Uppsala

Corem signed a four-year lease with Rarity Bioscience for approximately 1,300 sq.m. of laboratory and office space at Fyrislund 6:6 in Uppsala Business Park. The expansion provides Rarity Bioscience, a developer of cancer-mutation detection technology, with larger premises to support continued business development. The lease is a modestly positive occupancy development for Corem.

Analysis

The lease is directionally supportive for CORE.B because specialist laboratory occupancy typically carries higher tenant-retention value and fit-out switching costs than conventional office space. However, the contract is too small relative to a listed landlord’s portfolio to alter earnings expectations; the investable signal is whether this marks repeatable absorption in Uppsala life-science assets and whether tenant-improvement costs are being recovered through rent and indexation.

Over the next 1-3 months, the relevant catalyst is leasing disclosure: a sequence of lab-oriented tenants, rising occupancy, or positive rental reversion would support a lower vacancy-risk discount in CORE.B. Conversely, a single four-year term leaves meaningful rollover risk by 2030, while bespoke lab adaptations can create residual-capex exposure if the tenant does not renew. The market should demand evidence that the property’s conversion economics exceed those of standard office leasing rather than capitalize this announcement as a broad portfolio inflection.

The 6-18 month second-order opportunity is Uppsala’s life-science cluster: successful scaling by tenants can increase demand for adjacent flexible lab capacity, favoring landlords with suitable power, ventilation, and permitting. The contrarian view is that early-stage biotech tenant credit quality is more cyclical than the defensive healthcare label implies; tighter biotech funding conditions could turn apparent demand strength into elevated default or sublease risk.

Key Decisions for Investors

• No standalone trade on this announcement; maintain CORE.B on a leasing watchlist until management discloses rent, tenant-improvement capex, occupancy impact, and whether the lease is above current estimated rental value.
• Consider a tactical long CORE.B only after quarterly reporting confirms sequential occupancy improvement and stable or improving net operating income margins; target a 3-6 month rerating from reduced vacancy concerns, with thesis invalidated by renewed negative rental reversion or higher leasing capex.
• For existing CORE.B exposure, monitor biotech funding conditions and Rarity Bioscience’s financing runway over the next 12 months. Treat tenant-credit deterioration, early subleasing, or a rise in Uppsala vacancy as reasons to reduce exposure rather than extrapolate life-science demand.
• Relative-value screen: compare CORE.B’s implied property yield and office vacancy exposure against Swedish listed peers with more defensive logistics or residential income. A long CORE.B position is more compelling only if lab-leasing traction narrows its valuation discount without requiring disproportionate capital expenditure.